BioSpace News Archive

Ankyra Therapeutics, an emerging clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced data from a preclinical study using ANK-101, an IL-12 anchored therapeutic, in combination with cytotoxic chemotherapy and immune checkpoint blockade, to treat head and neck squamous cell carcinoma, modeled by murine oral carcinoma (MOC1).

ImCheck Therapeutics presented today updated data from its ongoing Phase I/IIa EVICTION-2 clinical trial at the Society for Immunotherapy of Cancer 38th annual meeting in San Diego, USA.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Cytokinetics, Incorporated announced that on October 31, 2023 it granted stock options to purchase an aggregate of 22,350 shares of common stock to five new employees, whose employment commenced in October 2023, as a material inducement to their employment.

Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 9, 2023, to review the company’s third quarter 2023 financial results and provide business updates.

TransMedics Group, Inc. announced that on November 1, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 27,520 shares of its common stock and an aggregate of 17,670 restricted stock units to 10 employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it will report third quarter 2023 financial and operating results on Tuesday, November 14, 2023.

Fulgent Genetics, Inc. announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer 38th Annual Meeting in San Diego, CA.